With a market capitalization (market cap) of $4.92B — a measure of how much the company is worth — Indivior Pharmaceuticals Inc is the 1439th most valuable company in Healthcare as of August 18, 2026. Shares trade at $39.43, up +0.90% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Visit websiteAs of August 18, 2026, Indivior Pharmaceuticals Inc (INDV) is worth $4.92B — this is its market capitalization, the total value of all its outstanding shares.
Indivior Pharmaceuticals Inc’s market cap is $4.92B, which ranks it #1439 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Indivior Pharmaceuticals Inc (INDV) shares trade at $39.43, up 0.90% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Indivior Pharmaceuticals Inc trades at a price-to-earnings (P/E) ratio of 23.5, based on its latest share price and annual earnings per share.